Declan F Doherty1, Sridesh Nath2, Justin Poon2, Robert F Foronjy2,3, Michael Ohlmeyer4,5, Abdoulaye J Dabo2,3, Matthias Salathe6,7, Mark Birrell8,9, Maria Belvisi8,9, Nathalie Baumlin6,7, Michael D Kim6,7, Sinéad Weldon1, Clifford Taggart1, Patrick Geraghty2,3. 1. 1 Airway Innate Immunity Research Group, Centre for Experimental Medicine, Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom. 2. 2 Division of Pulmonary and Critical Care Medicine, Department of Medicine, and. 3. 3 Department of Cell Biology, State University of New York Downstate Medical Centre, Brooklyn, New York. 4. 4 Icahn School of Medicine at Mount Sinai, New York, New York. 5. 5 Atux Iskay LLC, Plainsboro, New Jersey. 6. 6 Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas. 7. 7 Division of Pulmonary, Critical Care, and Sleep Medicine, University of Miami, Miami, Florida. 8. 8 Respiratory Pharmacology Group, Airway Disease Section, National Heart and Lung Institute, Imperial College, London, United Kingdom; and. 9. 9 Respiratory, Inflammation and Autoimmunity, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, London, United Kingdom.
Abstract
Rationale: CTSS (cathepsin S) is a cysteine protease that is observed at higher concentrations in BAL fluid and plasma of subjects with chronic obstructive pulmonary disease (COPD). Objectives: To investigate whether CTSS is involved in the pathogenesis of cigarette smoke-induced COPD and determine whether targeting upstream signaling could prevent the disease. Methods: CTSS expression was investigated in animal and human tissue and cell models of COPD. Ctss-/- mice were exposed to long-term cigarette smoke and forced oscillation and expiratory measurements were recorded. Animals were administered chemical modulators of PP2A (protein phosphatase 2A) activity. Measurements and Main Results: Here we observed enhanced CTSS expression and activity in mouse lungs after exposure to cigarette smoke. Ctss-/- mice were resistant to cigarette smoke-induced inflammation, airway hyperresponsiveness, airspace enlargements, and loss of lung function. CTSS expression was negatively regulated by PP2A in human bronchial epithelial cells isolated from healthy nonsmokers and COPD donors and in monocyte-derived macrophages. Modulating PP2A expression or activity, with silencer siRNA or a chemical inhibitor or activator, during acute smoke exposure in mice altered inflammatory responses and CTSS expression and activity in the lung. Enhancement of PP2A activity prevented chronic smoke-induced COPD in mice. Conclusions: Our study indicates that the decrease in PP2A activity that occurs in COPD contributes to elevated CTSS expression in the lungs and results in impaired lung function. Enhancing PP2A activity represents a feasible therapeutic approach to reduce CTSS activity and counter smoke-induced lung disease.
Rationale: CTSS (cathepsin S) is a cysteine protease that is observed at higher concentrations in BAL fluid and plasma of subjects with chronic obstructive pulmonary disease (COPD). Objectives: To investigate whether CTSS is involved in the pathogenesis of cigarette smoke-induced COPD and determine whether targeting upstream signaling could prevent the disease. Methods: CTSS expression was investigated in animal and human tissue and cell models of COPD. Ctss-/- mice were exposed to long-term cigarette smoke and forced oscillation and expiratory measurements were recorded. Animals were administered chemical modulators of PP2A (protein phosphatase 2A) activity. Measurements and Main Results: Here we observed enhanced CTSS expression and activity in mouse lungs after exposure to cigarette smoke. Ctss-/- mice were resistant to cigarette smoke-induced inflammation, airway hyperresponsiveness, airspace enlargements, and loss of lung function. CTSS expression was negatively regulated by PP2A in human bronchial epithelial cells isolated from healthy nonsmokers and COPD donors and in monocyte-derived macrophages. Modulating PP2A expression or activity, with silencer siRNA or a chemical inhibitor or activator, during acute smoke exposure in mice altered inflammatory responses and CTSS expression and activity in the lung. Enhancement of PP2A activity prevented chronic smoke-induced COPD in mice. Conclusions: Our study indicates that the decrease in PP2A activity that occurs in COPD contributes to elevated CTSS expression in the lungs and results in impaired lung function. Enhancing PP2A activity represents a feasible therapeutic approach to reduce CTSS activity and counter smoke-induced lung disease.
Authors: Jaya Sangodkar; Abbey Perl; Rita Tohme; Janna Kiselar; David B Kastrinsky; Nilesh Zaware; Sudeh Izadmehr; Sahar Mazhar; Danica D Wiredja; Caitlin M O'Connor; Divya Hoon; Neil S Dhawan; Daniela Schlatzer; Shen Yao; Daniel Leonard; Alain C Borczuk; Giridharan Gokulrangan; Lifu Wang; Elena Svenson; Caroline C Farrington; Eric Yuan; Rita A Avelar; Agnes Stachnik; Blake Smith; Vickram Gidwani; Heather M Giannini; Daniel McQuaid; Kimberly McClinch; Zhizhi Wang; Alice C Levine; Rosalie C Sears; Edward Y Chen; Qiaonan Duan; Manish Datt; Shozeb Haider; Avi Ma'ayan; Analisa DiFeo; Neelesh Sharma; Matthew D Galsky; David L Brautigan; Yiannis A Ioannou; Wenqing Xu; Mark R Chance; Michael Ohlmeyer; Goutham Narla Journal: J Clin Invest Date: 2017-05-15 Impact factor: 14.808
Authors: Clifford C Taggart; Catherine M Greene; Stephen G Smith; Rodney L Levine; Paul B McCray; Shane O'Neill; Noel G McElvaney Journal: J Immunol Date: 2003-07-15 Impact factor: 5.422
Authors: Polina Golovatch; Becky A Mercer; Vincent Lemaître; Alison Wallace; Robert F Foronjy; Jeanine D'Armiento Journal: Exp Lung Res Date: 2009-10 Impact factor: 2.459
Authors: Sridesh Nath; Michael Ohlmeyer; Matthias A Salathe; Justin Poon; Nathalie Baumlin; Robert F Foronjy; Patrick Geraghty Journal: Am J Respir Cell Mol Biol Date: 2019-11 Impact factor: 6.914
Authors: Abdoulaye J Dabo; Wendy Ezegbunam; Anne E Wyman; Jane Moon; Christopher Railwah; Alnardo Lora; Susan M Majka; Patrick Geraghty; Robert F Foronjy Journal: Am J Respir Cell Mol Biol Date: 2020-05 Impact factor: 6.914
Authors: Alexander D Verin; Robert Batori; Anita Kovacs-Kasa; Mary Cherian-Shaw; Sanjiv Kumar; Istvan Czikora; Vijaya Karoor; Derek Strassheim; Kurt R Stenmark; Evgenia V Gerasimovskaya Journal: Am J Physiol Cell Physiol Date: 2020-05-20 Impact factor: 4.249
Authors: Melissa Rivas; Gayatri Gupta; Louis Costanzo; Huma Ahmed; Anne E Wyman; Patrick Geraghty Journal: Medicina (Kaunas) Date: 2022-06-17 Impact factor: 2.948
Authors: Laura V Bownes; Raoud Marayati; Colin H Quinn; Andee M Beierle; Sara C Hutchins; Janet R Julson; Michael H Erwin; Jerry E Stewart; Elizabeth Mroczek-Musulman; Michael Ohlmeyer; Jamie M Aye; Karina J Yoon; Elizabeth A Beierle Journal: Cancers (Basel) Date: 2022-04-13 Impact factor: 6.639
Authors: Molly Easter; Jaleesa Garth; Elex S Harris; Ren-Jay Shei; Eric S Helton; Yuhua Wei; Rebecca Denson; Rennan Zaharias; Steven M Rowe; Patrick Geraghty; Christian Faul; Jarrod W Barnes; Stefanie Krick Journal: Front Med (Lausanne) Date: 2020-07-24